Every material Form 8-K biote Corp. has filed with the SEC since June 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Biote reported third-quarter 2026 revenue of $43.3 million, down 9.6% from $48.0 million a year earlier, and net income of $0.6 million, or $0.01 per diluted share, versus $9.2 million, or $0.22, in the prior-year quarter. The company kept its full-year 2026 guidance of revenue above $175 million and adjusted EBITDA above $25 million, and its interim CEO said a recent rise in procedure volume suggests demand is stabilizing, though the return to growth is progressing more slowly than anticipated.
Revenue was $43.3 million, down 9.6% from $48.0 million; procedure revenue fell 15.1% to $28.9 million while dietary supplements revenue grew 7.3% to $12.0 million.
Gross profit margin was 67.7% versus 71.8%, primarily due to residual impacts of the voluntary recall in January 2026.
Adjusted EBITDA was $5.1 million versus $12.9 million; net income was $0.6 million, or $0.01 per diluted share, versus $0.22 a year earlier.
Full-year 2026 revenue (above $175 million) and adjusted EBITDA (above $25 million) outlook remains unchanged from the second-quarter earnings release.
Biote reported second-quarter 2026 revenue of $44.2 million, down 9.5% from $48.9 million a year earlier, and a net loss of $7.4 million, compared with net income of $3.9 million. The company said the January 2026 voluntary product recall drove the decline and revised its full-year 2026 outlook, now calling for revenue above $175 million and Adjusted EBITDA above $25 million, and delaying its expected return to year-over-year procedure revenue growth.
Q2 2026 revenue was $44.2 million, down 9.5%; procedure revenue fell 13.9% to $30.3 million, tied to the voluntary recall initiated in January 2026
Net loss was $(7.4) million, or $(0.23) per diluted share, versus net income of $3.9 million, or $0.10 per diluted share, in Q2 2025
Adjusted EBITDA was $5.6 million, down from $15.2 million; gross profit margin fell to 65.4% from 71.6%
2026 guidance: revenue above $175 million and Adjusted EBITDA above $25 million; procedure revenue still expected to decline year over year in Q3 and Q4
Biote CEO Bret Christensen resigns as CEO effective June 8, 2026, for family and personal reasons, and remains a director. CFO Robert Peterson becomes interim CEO and a director on the same date, and Marc Beer becomes Executive Chairman; the company reaffirmed its 2026 guidance.
Christensen's resignation is effective June 8, 2026; he will serve on the Board as a Class III director until the 2028 annual meeting.
Robert Peterson, currently CFO and Chief Business Officer, becomes interim CEO and director, and the Board increased its size to eight directors.
The company reaffirmed 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million, and the Board has retained an executive search firm to find CFO candidates.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every biote Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →